SpringWorks Therapeutics Inc
NASDAQ:SWTX 4:00:00 PM EDT
| Market Cap (Intraday) | 3.54B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $46.93 |
| 50-Day MA | $45.88 |
| 200-Day MA | $41.26 |
SpringWorks Therapeutics Inc Stock, NASDAQ:SWTX
100 Washington Boulevard, Stamford, Connecticut 06902
United States of America
Phone: +1.203.883.9490
Number of Employees: 368
Description
Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the application of a medicine approach to acquiring, developing, and commercializing medicines. Its pipeline includes Nirogacestat, Mirdametinib, Brimarafenib, SW-682, and EGFR Inhibitor. The company was founded in August 2017 and is headquartered in Stamford, CT.